Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy

European Journal of Clinical Pharmacology

Volumn 62, Issue 1, 2006, Pages 23-28

  Takata, Keiji ^a   Saruwatari, Junji ^a   Nakada, Naoyuki ^a   Nakagawa, Mizuna ^a   Fukuda, Koichiro ^b   Tanaka, Fujiho ^c   Takenaka, Shinobu ^b   Mihara, Shuichi ^d   Marubayashi, Toru ^d   Nakagawa, Kazuko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO CITY HOSPITAL   (Japan)

^c Department of Medicine   (Japan)

^d JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

Author keywords

Caffeine; Cytochrome P450 1A2; Gene polymorphism; Phenotype genotype analysis; Theophylline

Indexed keywords

1 METHYLURACIL; 5 ACETAMIDO 6 AMINO 3 METHYLURACIL; CAFFEINE; CYTOCHROME P450 1A2; METHYLXANTHINE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG DISPOSITION; ENZYME ACTIVITY; EXON; FEMALE; FREQUENCY ANALYSIS; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; JAPAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SLOW RELEASE FORMULATION; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ASTHMA; BRONCHODILATOR AGENTS; CAFFEINE; CYTOCHROME P-450 CYP1A2; DELAYED-ACTION PREPARATIONS; FEMALE; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; THEOPHYLLINE;

EID: 30844465991     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0057-z     Document Type: Article

References (28)

1. Dahlqvist R, Billing B, Ripe E (1984) Theophylline-clinical pharmacokinetics and therapeutic drug monitoring. Eur J Respir Dis Suppl 136:81-94
2. Weinberger M, Hendeles L (1996) Theophylline in asthma. N Engl J Med 334:1380-1388
3. Hendeles L, Iafrate RP, Weinberger M (1984) A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products. Clin Pharmacokinet 9:95-135
4. Sandra J, Timothy H, Burns R (1990) Theophylline toxicity: update. Ann Allergy 64:241-257
5. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J (1994) Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 343:1006-1008
6. Ohta K, Fukuchi Y, Grouse L, Mizutani R, Rabe KF, Rennard SI, Zhong NS (2004) A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med 98:1016-1024
7. Sarkar MA, Hunt C, Guzelian PS, Karnes HT (1992) Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos 20:31-37
8. Fuhr U, Doehmer J, Battula N, Wolfel C, Kudla C, Keita Y, Staib AH (1992) Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol 43:225-235
9. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423
10. Anzenbacher P, Anzenbacherová E (2001) Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 58:737-747
11. Rasmussen BB, Brix TH, Kyvik KO, Brøsen K (2002) The differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 12:473-478
12. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T (1994) Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotyping in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 3:413-421
13. Nakajima M, Yokoi T, Mizutani T, Kinoshita M, Funayama M, Kamataki T (1999) Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: Effect on the CYP1A2 inducibility in humans. J Biochem 125:803-808
14. Sachse C, Brockmöller J, Bauer S, Roots I (1999) Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449
15. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, Sundberg MI (2003) Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotype with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64:659-669
16. Murayama N, Soyama A, Saito Y, Nakajima Y, Komamura K, Ueno K, Kamakura S, Kitakaze M, Ozawa S, Sawada J (2004) Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 308:300-306
17. Kallow W, Tang BK (1993) The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 53:503-514
18. Obase Y, Shimoda T, Kawano T, Saeki S, Tomari S, Matsuse H, Kinoshita M, Kohno S (2003) Polymorphisms in the CYP1A2 gene and metabolism in patients with asthma. Clin Pharmacol Ther 73:468-474
19. Gu L, Gonzalez FJ, Kalow W, Tang BK (1992) Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2:73-77
20. Rasmussen BB, Brøsen K (1997) Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humans. Br J Clin Pharmacol 43:253-258
21. Rasmussen BB, Brøsen K (1996) Determination of theophylline and its metabolites in human urine and plasma by high-performance liquid chromatography. J Chromatogr B 676:169-174
22. Saruwatari J, Nakagawa K, Shindo J, Tajiri T, Fujieda M, Yamazaki H. Kamataki T, Ishizaki T (2002) A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clin Pharmacol Ther 72:200-208
23. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T (1999) Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 90:899-902
24. Welfare MR, Aitkin M, Bassendine MF, Daly AK (1999) Detailed modeling of caffeine metabolism and expression of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. Pharmacogenetics 9:367-375
25. Soyama A, Saito Y, Hanioka N, Maekawa K, Kamatani N, Ozawa S, Sawada J (2005) Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet 20:24-33
26. Cohen J (1969) F tests on means in the analysis of variance and covariance. In: Cohen J (ed) Statistical power analysis for the behavioral science. Academic Press, New York, pp 266-397
27. Han XM, Ou-Yang DS, Lu PX, Jiang CH, Shu Y, Chen XP, Tan ZR, Zhou HH (2001) Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 11:429-435
28. Bachmann K, White D, Jauregui L, Schwartz JI, Agrawal NGB, Mazenko R, Larson RJ, Porras AG (2003) An evaluation of the dose-dependent inhibition of CYP1A2 by Rofecoxib using theophylline as a CYP1A2 probe. J Clin Pharmacol 43:1082-1090